NCT04981509 2026-03-18
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
9 trialsNCT00001238 2026-03-16
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
National Institutes of Health Clinical Center (CC)
Recruiting
NCT04895748 2026-03-03
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Phase 1 Terminated
NCT04623502 2026-01-28
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
University of Texas Southwestern Medical Center
Phase NA Recruiting
NCT01130519 2025-02-21
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03749980 2024-04-26
MyVHL
VHL Alliance
Recruiting
NCT05534854 2023-08-31
Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes
RenJi Hospital
Unknown
NCT04603365 2023-05-17
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT00971620 2017-04-07
Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin
National Institutes of Health Clinical Center (CC)
Phase 2 Completed